Author

S. Jovic

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:CITE-seq· 1 Research Focus:differential expression· 1 Assay:DNA methylation· 1

Frequent Co-Authors

A. A. Mensah· 1 shared A. Cassotta· 1 shared A. Ceschi· 1 shared A. Franzetti Pellanda· 1 shared A. J. Arribas· 1 shared A. Lanzavecchia· 1 shared A. Rinaldi· 1 shared A. Stathis· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. A. Mensah

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms

A. J. Arribas, S. Napoli, L. Cascione, L. Barnabei, G. Sartori, E. Cannas, E. Gaudio, C. Tarantelli, A. A. Mensah, F. Spriano, A. Zucchetto, F. M. Rossi, A. Rinaldi, M. Castro de Moura, S. Jovic, , F. Bertoni

This study identifies ERBB4-mediated signaling as a mechanism of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms and shows that targeting ERBB signaling can restore sensitivity.

bioRxiv · Jan 1, 2023Cancer Biology

Clonal dissection of immunodominance and cross-reactivity of the CD4+ T cell response to SARS-CoV-2

J. S. Low, D. Vaqueirinho, F. Mele, M. Foglierini, M. Perotti, D. Jarrossay, S. Jovic, T. Terrot, A. Franzetti Pellanda, M. Biggiogero, C. Garzoni, P. Ferrari, A. Ceschi, A. Lanzavecchia, A. Cassotta, F. Sallusto

The paper identifies immunodominant and cross-reactive CD4+ T cell epitopes in SARS-CoV-2, showing their recognition in 93% of patients and potential for vaccine design.

bioRxiv · Mar 23, 2021Immunology